Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

被引：47

作者：

O'Brien, Thomas R. ^{[1
]}

Kuhs, Krystle A. Lang ^{[1
]}

Pfeiffer, Ruth M. ^{[2
]}

机构：

[1] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr,6E108,MSC 9767, Bethesda, MD 20892 USA

[2] Natl Canc Inst, Biostat Branch, Div Canc Epidemiol & Genet, Bethesda, MD USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2014年 / 1卷 / 03期

基金：

美国国家卫生研究院;

关键词：

clinical trial; cost-effectiveness; direct-acting antiviral agents; gender; hepatitis C virus; IFNL4;

D O I：

10.1093/ofid/ofu110

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Treatment of hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir for 8 weeks. After reanalyzing published ION-3 data, we found that sustained virologic response (SVR) rates varied significantly by gender (P = .002) and rs12979860 genotype (P-trend = .03), exceeding 98% in women and rs12979860-CC individuals. The very high SVR rates in these subgroups suggest that these factors might be considered in selecting patients to receive 8 weeks of ledipasvir/sofosbuvir and support shorter trials of this regimen in selected patients.

引用

页数：4

共 15 条

[1] Inconsistent Definitions for Intention-To-Treat in Relation to Missing Outcome Data: Systematic Review of the Methods Literature [J].

Alshurafa, Mohamad ;

Briel, Matthias ;

Akl, Elie A. ;

Haines, Ted ;

Moayyedi, Paul ;

Gentles, Stephen J. ;

Rios, Lorena ;

Tran, Chau ;

Bhatnagar, Neera ;

Lamontagne, Francois ;

Walter, Stephen D. ;

Guyatt, Gordon H. .

PLOS ONE, 2012, 7 (11)

[2] Chronic Hepatitis C Virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010 [J].

Denniston, Maxine M. ;

Jiles, Ruth B. ;

Drobeniuc, Jan ;

Klevens, R. Monina ;

Ward, John W. ;

McQuillan, Geraldine M. ;

Holmberg, Scott D. .

ANNALS OF INTERNAL MEDICINE, 2014, 160 (05) :293-+

[3] Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection [J].

Gane, Edward J. ;

Stedman, Catherine A. ;

Hyland, Robert H. ;

Ding, Xiao ;

Svarovskaia, Evguenia ;

Subramanian, G. Mani ;

Symonds, William T. ;

McHutchison, John G. ;

Pang, Phillip S. .

GASTROENTEROLOGY, 2014, 146 (03) :736-+

[4] Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].

Ge, Dongliang ;

Fellay, Jacques ;

Thompson, Alexander J. ;

Simon, Jason S. ;

Shianna, Kevin V. ;

Urban, Thomas J. ;

Heinzen, Erin L. ;

Qiu, Ping ;

Bertelsen, Arthur H. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

McHutchison, John G. ;

Goldstein, David B. .

NATURE, 2009, 461 (7262) :399-401

[5] Therapy for Hepatitis C - The Costs of Success [J].

Hoofnagle, Jay H. ;

Sherker, Averell H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (16) :1552-1553

[6] Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis [J].

Kowdley, Kris V. ;

Gordon, Stuart C. ;

Reddy, K. Rajender ;

Rossaro, Lorenzo ;

Bernstein, David E. ;

Lawitz, Eric ;

Shiffman, Mitchell L. ;

Schiff, Eugene ;

Ghalib, Reem ;

Ryan, Michael ;

Rustgi, Vinod ;

Chojkier, Mario ;

Herring, Robert ;

Di Bisceglie, Adrian M. ;

Pockros, Paul J. ;

Subramanian, G. Mani ;

An, Di ;

Svarovskaia, Evguenia ;

Hyland, Robert H. ;

Pang, Phillip S. ;

Symonds, William T. ;

McHutchison, John G. ;

Muir, Andrew J. ;

Pound, David ;

Fried, Michael W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1879-1888

[7] Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin [J].

Meissner, Eric G. ;

Nelson, Amy ;

Marti, Miriam ;

Masur, Henry ;

Osinusi, Anu ;

Kottilil, Shyam .

OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (01)

[8] IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin [J].

Meissner, Eric G. ;

Bon, Dimitra ;

Prokunina-Olsson, Ludmila ;

Tang, Wei ;

Masur, Henry ;

O'Brien, Thomas R. ;

Herrmann, Eva ;

Kottilil, Shyamasundaran ;

Osinusi, Anuoluwapo .

JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (11) :1700-1704

[9] IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family [J].

O'Brien, Thomas R. ;

Prokunina-Olsson, Ludmila ;

Donnelly, Raymond P. .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2014, 34 (11) :829-838

[10] A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus [J].

Prokunina-Olsson, Ludmila ;

Muchmore, Brian ;

Tang, Wei ;

Pfeiffer, Ruth M. ;

Park, Heiyoung ;

Dickensheets, Harold ;

Hergott, Dianna ;

Porter-Gill, Patricia ;

Mumy, Adam ;

Kohaar, Indu ;

Chen, Sabrina ;

Brand, Nathan ;

Tarway, McAnthony ;

Liu, Luyang ;

Sheikh, Faruk ;

Astemborski, Jacquie ;

Bonkovsky, Herbert L. ;

Edlin, Brian R. ;

Howell, Charles D. ;

Morgan, Timothy R. ;

Thomas, David L. ;

Rehermann, Barbara ;

Donnelly, Raymond P. ;

O'Brien, Thomas R. .

NATURE GENETICS, 2013, 45 (02) :164-171

← 1 2 →